Neoadjuvant chemotherapy can improve oncologic outcomes and overall survival rate. However, not all patients respond well during treatment, and continuous treatment will be painful, costly, and even increase risk of progression. Thus, early stratification of treatment response and screening of patients who may not be effective in treatment is very important. We investigated the value of T1 and T2 mapping MRI in response evaluation and found that T2 value showed a significant difference between groups of pre and 1-week post-treatment, while the T1 value had no statistical difference. T2 mapping may be a useful functional biomarker for early responses evaluation.